Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Sunitinib 27Nivolumab 26pembrolizumab 23Sorafenib 17Everolimus 14Cyclophosphamide 13Interleukin-2 10Bevacizumab 10Radiosurgery 9spartalizumab 8pazopanib 7atezolizumab 7Ipilimumab 7Axitinib 7fludarabine 6aldesleukin 6cabozantinib 5Radiotherapy 5Magnetic Resonance Spectroscopy 5Immunohistochemistry 5Gemcitabine 5peginterferon alfa-2b 4avelumab 4Nephrectomy 4Irinotecan 4Introns 4Gene Expression Profiling 4Capecitabine 4lenvatinib 3fludarabine phosphate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Renal Cell × Levoleucovorin × Clear all
NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

NuCana plc

Phase 1/2 Terminated
19 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡